上海外高桥集团股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召 开第十一届董事会第十三次会议、第十一届监事会第七次会议，审议通过了《关 于使用暂时闲置募集资金进行现金管理的议案》，同意公司在不影响募集资金投 资项目建设需要，且不影响公司正常生产经营及确保相关资金安全的前提下，使 用最高不超过 50,300 万元的闲置募集资金进行现金管理，购买安全性高、流动 性好的保本型理财产品或存款类产品，使用期限自董事会审议通过之日起 12 个 月内有效，在决议有效期内，上述额度可以循环滚动使用。保荐人对公司使用暂 时闲置募集资金进行现金管理的事项无异议。具体内容详见公司于 2025 年 7 月 22 日披露的《关于使用暂时闲置募集资金进行现金管理的公告》(公告编号：临 2025-034)。 一、公司募集资金现金管理到期赎回情况 证券代码：600648、900912证券简称：外高桥、外高 B 股 公告编号：临 2025-046 2025 年 8 月 28 日，公司控股子公司上海市外高桥保税区三联发展有限公司 与中国光大银行股份有限公司上海分行签署了对公结构性存款合同，于近日赎回， | 产品名 | | 受 ...

近日，"中信建投（601066）-外高桥（600648）集团持有型不动产资产支持专项计划"在上交所设立， 发行规模18.30亿元，这是市场首单以工业厂房作为底层资产的持有型不动产ABS(以下称为机构间 REITs)。 工业厂房类资产首次入池 项目存续期间，计划管理人提供包括交易撮合、报价服务在内的二级交易支持，以提高产品二级市场流 动性。同时项目开创性地采用"基准收益+超额收益"的分配机制，超额收益可在产品发行后持续吸引市 场潜在投资人的关注，促使多元化机构群体参与配置，提高证券交易活跃度，从而进一步提升产品二级 市场流动性。此外，产品还设置了灵活的扩募机制，可持续将优质工业厂房项目装入该资产上市平台， 实现"投、融、管、退"的良性循环。 中信建投相关负责人表示："未来，中信建投证券将积极研究在机构间REITs中引入基金经理制度，由基 金经理作为项目公司高管，切实做好存续期间底层资产的运营管理，通过资产管理提升产品价值。" 外高桥集团相关负责人表示："外高桥集团历经30多年的开发运营，积累了丰富的经营性物业资源。但 这些物业以租赁为主、销售为辅，因此，资金回收周期较长、资产周转率较低、资产流动性较弱。公司 通 ...

一、公募REITs基本信息 周晴女士简历如下： 周晴女士，42岁，中国国籍，硕士。现任上海外联发商务咨询有限公司副总经理职务。曾任上海外联发 商务咨询有限公司金融咨询部总监等职务，拥有9年投资管理经验。 运营管理机构已就前述事项履行完成内部决议程序。 四、对基础设施项目运营情况、经营业绩、现金流和基金份额持有人权益的影响分析 目前运营管理机构经营管理团队稳定，履职正常，本次运营管理实施机构高级管理人员变动系正常人事 调整，不影响机构稳定运营管理能力，对基础设施项目运营情况、经营业绩、现金流和基金份额持有人 权益无不利影响。 本公告内容已经本基金运营管理机构确认。 ■ 三、运营管理机构高级管理人员变更情况 本基金管理人于2025年11月28日收到运营管理机构通知，因工作调整，运营管理实施机构高级管理人员 变更情况如下： 增聘周晴女士担任运营管理实施机构上海外联发商务咨询有限公司副总经理职务。 ■ 二、基础设施项目基本情况 投资人可以通过本基金管理人网站（www.huaan.com.cn）或客户服务电话40088-50099咨询有关详情。 六、风险提示 基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产， ...

11月28日，海关总署牵头的国家十部委对上海东方枢纽国际商务合作区先行启动区进行联合验收，并颁发验收合格证书。同日，智通财经记者从 上海外高桥集团获悉，位于"东方枢纽"核心区的上海外高桥，已于11月27日启动首个"脑机接口创新发展伙伴计划"，同步发布"外高桥脑机接口产 品服务包"。这也标志着外高桥将这一前沿科技纳入其核心产业版图，致力于打造生物医药产业"加速器"。 11月27日，上海外高桥"脑机接口创新发展伙伴计划"发布现场。智通财经实习记者 张云鹏 摄 "外高桥给企业的帮助是多元化的，从政策到资源，全方位为企业保驾护航。"上海阶梯医疗科技有限公司总经理助理陈垚旭告诉智通财经记者， 作为国内侵入式脑机接口领域的创新代表，企业不仅获得了专业的政策解读与市场准入辅导，还通过政府资源对接与合作生态协同，快速链接行 业优质资源。 陈垚旭透露，对于东方枢纽商务合作区未来可能推出的数据跨境功能，企业也寄予厚望。长期来看，这一功能对脑机接口领域的跨国研发、多中 心研发意义重大，现阶段公司已在学习相关政策与流程，为未来布局做好准备。 "中国脑机接口产业与美国差距不大，部分领域已实现超越。"外高桥生物医药公司总经理诸耀鹏告诉智 ...

Core Insights - The Waigaoqiao Group has launched the "Brain-Computer Interface Innovation Development Partnership Program" to enhance its position in the brain-computer interface (BCI) sector, aiming to become a preferred "landing point" and "accelerator" for BCI innovations [1] Group 1: Partnership Program Details - The partnership program aims to unite enterprises, hospitals, and government departments to collaboratively build an innovative ecosystem that addresses bottlenecks in clinical transformation, cross-border data, and market access for BCI technology [1] - Participating companies will receive the "Waigaoqiao Brain-Computer Interface Product Service Package," which includes comprehensive support from cross-border R&D pilot projects to clinical approval acceleration and market expansion [1] - Initial participants will also benefit from preferential support in terms of space and guidance on relevant industrial policies provided by the Waigaoqiao Group [2] Group 2: Industry Context and Developments - The BCI sector is on the verge of transitioning from laboratory research to clinical application, with companies aiming to establish a full-service capability from R&D to market entry to capture future industry opportunities [2] - Recently, Ladder Medical's "Implantable Wireless Brain-Computer Interface System" has entered the special review process by the National Medical Products Administration, marking a significant milestone for invasive BCI products in China [2] - Ladder Medical has developed the world's smallest brain-controlled implant and is progressing towards full domestic production, collaborating with Fudan University Huashan Hospital for prospective clinical trials [2] Group 3: Strategic Advantages - The development of BCI technology relies heavily on interdisciplinary collaboration, cross-border R&D, and international cooperation, which aligns with Waigaoqiao's strategic advantages [3] - Waigaoqiao offers "bonded R&D" policy functions and serves as a hub connecting domestic and international markets, facilitating data cross-border and personnel movement [3] - The company provides comprehensive policy adaptation services for BCI enterprises, covering the entire process from clinical trials to overseas registration [4]

Core Viewpoint - The establishment of the "CITIC Construction Investment - Waigaoqiao Group Holding-type Real Estate Asset-backed Special Plan" marks a significant development in the asset-backed securities (ABS) market, particularly for state-owned enterprises in Shanghai, showcasing strong investor interest and a new model for revitalizing state-owned assets [1][2]. Group 1 - The project was initiated by Waigaoqiao Group as the original rights holder, with CITIC Construction Investment Securities acting as the plan manager and lead sales agency [1]. - The underlying assets consist of four industrial plant projects owned by Waigaoqiao Group, managed by its subsidiary, Shanghai Waigaoqiao Free Trade Zone New Development Co., Ltd [1]. - The issuance was conducted through a price inquiry method, with a range of 1.776 billion to 1.83 billion yuan, ultimately achieving a total issuance size of 1.83 billion yuan, attracting 21 investors from various sectors including insurance, bank wealth management, and local state-owned assets [1]. Group 2 - Waigaoqiao Group is recognized as the first developer and operator of the national bonded zone, bonded logistics park, and free trade zone, responsible for comprehensive development, investment attraction, industry cultivation, and property management services in the region [2]. - The selected underlying assets include four high-quality industrial plant projects located in the Waigaoqiao area, with a total building area of approximately 190,600 square meters and an average occupancy rate of 93.16% [2]. - The tenants include companies from industries such as IDC data centers, intelligent manufacturing, and biopharmaceutical research and development, aligning with regional industrial development strategies [2].

（文章来源：证券日报） 证券日报网讯外高桥11月20日在互动平台回答投资者提问时表示，截至2025年第三季度末，公司股东总 数为48547户，详见公司于2025年10月31日披露的定期报告。 ...

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - Changlian Co., Ltd. will invest 30 million yuan, accounting for 60% of the registered capital of the new company [1] - The registered capital of the new company is set at 50 million yuan, with a profit distribution ratio of no less than 60% of the annual net profit [1] - The investment is expected to be completed by January 30, 2026 [1]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, with Changlian Co. contributing 30 million yuan, which represents 60% of the new company's registered capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, and the new company will be established with a registered capital structure where Changlian Co. will contribute 30 million yuan, representing 60% of the total capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]